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Abstract 
 
There is increasing demand from in vitro method developers, validation 
bodies, in vitro method end-users as well as receiving authorities and 
OECD to integrate kinetics information in toxicity testing in order to 
improve chemical risk assessment. A strategic way to do this is detailed in 
the "EURL ECVAM strategy for achieving 3Rs impact in the assessment of 
toxicokinetics and systemic toxicity" (Bessems J et al. 2015). One of the 
strategic aims of this report urges for the development and applied use of 
in vitro kinetic methods for absorption, distribution, metabolism and 
excretion to be used in the future risk assessment approaches using new 
advanced methodologies (NAMs). 
Information on metabolism has been identified as a critical piece of 
information in integrated test strategies based on non-animal methods. 
Therefore, the purpose of this report is to describe the preliminary 
experimental work towards a representative in vitro human hepatic 
metabolic clearance method that can be ultimately used in future defined 
approaches for toxicological risk assessment. 
The proposed method is a result of the efforts of the EURL ECVAM 
laboratory team combined with knowledge gathered during (1) a 
literature search on in vitro human hepatic metabolic clearance methods, 
(2) an EURL ECVAM call for procedures detailing in vitro human hepatic 
metabolic clearance methods and (3) an expert meeting to establish the 
elements critical for in vitro methods that predict human hepatic 
metabolic clearance. The representative in vitro human hepatic metabolic 
clearance method was used to assess the in vitro intrinsic clearance of the 
following three chemicals: Acetaminophen, Diclofenac and Verapamil. 
Each chemical was added at one concentration to cryopreserved primary 
human hepatocytes (pooled from 10 donors) and the cells were exposed 
at different incubation time-points up to 2 h. The concentrations of each 
chemical over-time were measured by using Ultra-Performance Liquid-
Chromatography (UPLC) coupled with (Quadrupole Time-of-Flight) Q-Tof 
mass spectrometer. 
The results obtained show good within-laboratory reproducibility (e.g.  
between different runs on different days), of the calculated in vitro 
intrinsic clearance. 
The results and experience gained with this experimental in-house effort 
by Directorate F – Health, Consumers and Reference Materials, F.3 
Chemicals Safety and Alternative Methods will support the definition of an 
EURL ECVAM recommendation on human hepatic metabolic clearance and 
the subsequent drafting of a proposal for an OECD Guidance Document 
with the objective to characterise and describe in vitro hepatic metabolic 
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clearance methods in order to facilitate their regulatory uptake and use to 
support chemical risk assessment.  
  
3 
1 Introduction 
Kinetics describes the concentration-time profile of a chemical in a 
biological system (e.g. human body, organ, tissue, cell). In other words, 
it describes what the body (or cell) does to a chemical and it is the 
opposite of dynamics which describes what a chemical does to the body 
(or cell). 
Kinetics is the result of 4 processes: Absorption, Distribution, Metabolism 
and Excretion (ADME). Metabolism (chemical bio-transformation or 
'metabolic clearance') is a critical factor in determining kinetic behaviour 
of compounds of various kinds. Metabolism can occur in several organs 
and tissues in the body. Nevertheless, the liver is the main site 
responsible for metabolic clearance. 
In short, human hepatic metabolic clearance represents in many cases 
one of the two most important determinants of the concentration-time 
profile of a chemical, the other one being the human absorption kinetics. 
Therefore, hepatic metabolic clearance data can represent an 
indispensable information source to support the chemical risk assessment. 
In fact, there is increasing demand (from in vitro method developers, 
validation bodies, in vitro method end-users as well as receiving 
authorities and OECD) to integrate kinetics information in toxicity testing 
in order to improve chemical risk assessment. (EURL-ECVAM TK Strategy, 
Bessems J et al. 2015 [1]).  
Exposure to a chemical does not automatically mean that all of the dose 
will be bioavailable and therefore able to cause a specific toxicity. Hence 
the knowledge of the chemical concentration-time profile in a biological 
system (therefore the chemical kinetics) can assist to better design 
toxicity tests (both in vivo and in vitro) and interpret toxicological findings 
by: 
 selecting the most relevant doses to be administered (e.g. avoid 
doses which can cause saturation of metabolism which then will 
lead to general systemic toxicity effects); 
 selecting the most sensitive animal species which can provide 
valuable information relevant to human biology (e.g. improve the 
extrapolation from animal toxicological data and assess relevance 
for humans); 
 waiving toxicity tests which can reduce the use of laboratory 
animals (e.g. if kinetics data indicate that a chemical bio-
accumulates in the body then chronic toxicity studies are more 
relevant than acute-studies); 
 improving the design on in vitro tests and the interpretation of 
the data generated (e.g. evaluate if in vitro metabolism is similar 
to the in vivo counterpart to then assess the relevance of the 
data when making in vitro to in vivo extrapolation). 
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There are several other applications where knowledge of kinetics can 
support and improve chemical risk assessment and a more detailed 
discussion can be found in EURL-ECVAM TK Strategy (Bessems J et al. 
2015 [1]). In several EU chemical management legislations (REACH [2], 
CPR [3], PPPR [4], BPR [5]) it is required or recommended information 
on obtaining kinetics data. A more detailed overview was published in the 
EURL-ECVAM TK Strategy (Bessems J et al. 2015 [1]). 
Since modern toxicology relies more on the use of alternative methods to 
animal toxicity testing, methods are being developed/used to provide 
kinetics information. 
Therefore, considering that human hepatic metabolic clearance plays a 
key role in determining kinetics, there are already several non-guideline 
in vitro methods to measure in vitro human hepatic metabolic clearance 
and these methods can significantly vary for the experimental-settings, 
stage of development, intended use, reliability, relevance, etc. 
Following the above considerations, the purpose of this project was to 
implement in EURL ECVAM laboratory facility an in vitro metabolic hepatic 
clearance method in order to build the in-house expertise to perform this 
type of studies which can serve multiple research works focused on 
supporting chemical risk assessment by using alternative to animal 
toxicity testing methods. 
The development of an in vitro human hepatic metabolic clearance 
method (or in vitro clearance method) in the EURL ECVAM laboratory 
facility was based on previous work which is described in more details in 
the following two deliverables recently published: 
 EURL ECVAM literature survey to identify publically available in 
vitro human hepatic metabolic clearance/ stability methods 
(2014) [6] 
 EURL ECVAM web survey on in vitro human hepatic metabolic 
clearance/ stability methods (2014) [7] 
Briefly, the EURL ECVAM established a process to map existing in vitro 
human hepatic metabolic clearance methods in order to evaluate the 
experimental conditions used across various settings.  
The ultimate goal (which is part of the Work Programme of Directorate F 
– Health, Consumers and Reference Materials, F.3 Chemicals Safety and
Alternative Methods and object of future planned deliverables) is to 
develop a Guidance Document (to be submitted to the OECD) which 
serves to: i) characterise and report the most important elements and 
attributes of in vitro hepatic metabolic clearance methods; ii) evaluate 
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their performance and iii) report all this information in a structured and 
easily accessible way. 
The reason to have such Guidance is that there are several in vitro 
metabolic clearance methods which differ in their experimental design and 
for the application they are used for. Therefore there is a guidance is  
needed on how to evaluate if the available (or new) methods produce 
relevant information that can be used to support chemical risk 
assessment. 
 
In order to contribute in achieving the above objective of developing a 
Guidance Document, the process established by EURL ECVAM to map 
existing in vitro clearance methods consisted in a collective knowledge-
gathering exercise involving: a literature survey, a test submission e-
survey and an expert workshop.  
Based on all the information gathered covering several existing in vitro 
metabolic clearance methods, a representative in vitro metabolic 
clearance method was identified (Figure 1). 
 
Figure 1 
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This representative method is not meant to be the "best possible" in vitro 
human hepatic metabolic clearance method but simply indicates the most 
common used experimental layout (fitted for specific purposes) built on 
existing experience collected from available in vitro clearance methods. 
Therefore the representative methods can be considered as having a set 
of experimental elements that, based on practical experience, have 
proven to generate reliable and relevant data. 
Before describing in the Materials and Methods section the work done to 
implement the representative method, the following discussion will 
provide a general description of possible approaches to develop in vitro 
hepatic metabolic clearance methods. 
In vitro human hepatic metabolic clearance is commonly measured using 
hepatocytes suspension cultures (generally collected from human liver 
which are called "primary hepatocytes" or from cancer cells) or hepatic 
microsomes (sub-cellular fractions). In contrast to microsomes 
(representing only the Phase I biotransformation enzymes of human liver 
since they are lacking conjugation activities), the use of primary human 
hepatocytes (fresh or cryopreserved) is widely accepted as the most 
appropriate in vitro system since all the metabolic enzymes (Phase I and 
Phase II biotransformation enzymes) but also transporters are present in 
a physiological relevant set-up. A typical experiment consists in exposing 
the hepatocytes to one concentration of the chemical to be tested (the 
concentration should be below cytotoxicity) in order to determine intrinsic 
clearance (CLint). 
CLint is expressed as μL/(min*millions of cells) and indicates the volume 
cleared by the chemical (due to metabolism) per minute and per million 
of hepatocytes used in the experiment. Therefore CLint refers to enzyme-
mediated clearance that would occur without physiological limitations 
(e.g. protein binding, hepatic blood flow). 
In general, two approaches are used to determine CLint: metabolite 
formation and substrate depletion. For metabolite formation, the chemical 
is exposed to hepatocytes at one concentration over several time-points 
and the formation of the metabolites is measured. This requires the 
knowledge of which metabolites are formed and therefore this approach is 
technically demanding and not always feasible when there prior 
knowledge of the metabolites is lacking. 
The second approach, named substrate depletion, entails the incubation 
of the hepatocytes exposed to the test compound at one concentration 
and the measurement of its disappearance over time. This approach is 
technically easier to be performed and in fact it is the most common in 
vitro metabolic clearance method. 
 
The method implemented in the EURL ECVAM laboratory facilities made 
use of a suspension culture of pooled cryopreserved primary human 
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hepatocytes (collected from 10 different donors). The CLint was measured 
by using the substrate depletion approach for 3 monoconstituent 
substrates used as reference chemicals with available in vivo hepatic 
clearance data, e.g. acetaminophen, diclofenac and verapamil. 
 
 
2 Materials and methods 
 
2.1 General experimental layout 
 
 
2.2 Materials 
2.2.1 Chemicals: 
− Acetaminophen 
(CAS No. 103-90-2, Sigma-Aldrich) 
− Acetaminophen-D4 
(CAS No. 64315-36-2, Sigma-Aldrich) used as internal standard for 
acetaminophen 
 8 
 
− Diclofenac sodium salt 
(CAS No. 15307-79-6, Sigma-Aldrich) 
− Diclofenac 13C6 sodium salt 4.5 hydrate 
(CAS No. 1261393-73-0, Sigma-Aldrich) used as internal standard 
for diclofenac 
− Verapamil hydroxychloride 
(CAS No. 152-11-4, Sigma-Aldrich)  
− Verapamil-D7 Hydrochloride 
(CAS No. 1188265-55-5, LGC Standards) used as internal standard 
for verapamil hydroxychloride 
 
2.2.2 Cells, cell media and additives: 
− 10 donor pool of cryopreserved primary human hepatocytes for 
suspension use (provider Bioreclamation-ITV, X008001) 
− InVitroGRO Hepatocytes Thawing medium 
(BioreclamationITV, Z99019) 
− Williams’ Medium E (W1878 Sigma) 
− Insulin, Transferrin, Selenium (ITS) (41400045 Gibco) 
− L-Glutamine 200mM (25030149 Gibco) 
− Hepes, (1M, pH 7.4) (Gibco 15630080) 
 
2.2.3 Plastic ware and disposable: 
 
− Sterile 96-well clear polypropylene plates with lid, round bottom, 
uncoated 
− Sterile 15-mL polypropylene centrifuge tubes  
− Sterile 50-mL polypropylene centrifuge tubes  
− Sterile polypropylene reagent reservoir of at least 20 mL size  
− Adjustable pipette 2-20 μL 
− Adjustable pipette 10-100 μL 
− Adjustable pipette 100-1000 μL 
− Sterile pipette tips 
 
 
2.2.4 Technical equipment: 
− Water bath able to maintain a temperature of 37°C 
− Cell incubator with 5 ± 1% CO2 atmosphere, 37± 2°C temperature 
and with water-saturated atmosphere 
− Orbital shaker able to operate at water-saturated atmosphere 
− Balance with at least 0.01 mg readability 
− Centrifuge appropriate for 96-well plates and able to maintain a 
temperature of 4 oC  
− Heating plate with internal regulator to maintain 37oC 
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2.2.5 Reagents used for chemical analysis: 
− Acetonitrile (UPLC grade) 
− Formic acid (UPLC grade) 
− Ultrapure water 18.2MΩ.cm 
 
2.2.6 Analytical equipment 
UPLC Acquity coupled with Xevo G2-S QTof (Waters) 
 
2.3 Preparation of cell assay medium, stock and working 
solutions 
The following sections describe the preparation of the different reagents 
and solutions used to perform the in vitro metabolic hepatic clearance 
method. 
Table 1 summarises the reagents and solutions to be prepared and the 
time for their preparation. 
Table 1 
To be prepared the day before the experiment 
The cell medium to be used for incubation assay (section 2.3.1) 
The mixture of cell medium and acetonitrile (50:50) (section 2.3.2) 
The stop solutions with specific internal standard at 1 µM (section 2.3.3) 
The5 mL stock concentration of 10 mM for each chemical to be tested (section 2.3.4.) 
To be prepared the day of the experiment 
The working concentration of 2 µM for each chemical to be tested (section 2.3.5) 
The chemical standards for the calibration curve for LC-MS analysis (section 2.3.6) 
 
2.3.1 Cell medium for incubation assay: 
 
In a bottle containing 500mL of Williams's Medium E the following steps 
were done: 
 Addition of 0.5mL of ITS (Insulin, Transferrin, Selenium) 
 Addition of 5mL of L-Glutamine 200mM 
 Addition of 7.5mL of HEPES 
 Thorough shaking and labelling as “Cell medium for incubation 
assay” 
 An expiry date of 1 month was assigned 
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2.3.2 Cell medium and acetonitrile mixture (50:50): 
 
To obtain the mixture the following procedure was adopted: 
 Addition of 10mL of "Cell medium for incubation assay" into a 
20mL volumetric flask and making up to the mark with acetonitrile 
 Thorough shaking and labelling as “Cell medium-acetonitrile 
50:50” 
 An expiry date of 1 day was assigned 
 
 
2.3.3 Stop solutions using specific internal standards 
 
Note: For each of the 3 chemicals tested, a specific internal standard was 
used to then performed the chemical analysis by using mass 
spectrometry 
 To have a 2mM concentration, a defined amount of mg of the 
desired Internal Standard was weighted and transferred in a 5mL 
volumetric flask 
 About 3mL of acetonitrile (or another solvent depending on the 
solubility) were added and checked to ensure that all the powder 
was dissolved. Then making up to the mark with acetonitrile 
 Then a thorough shaking was done and after transferred in a glass 
tube and labelled as "Internal standard (either for Acetaminophen, 
Diclofenac or Verapamil) 2mM in acetonitrile" 
 An expiry date of 6 months was assigned 
 In a 10mL volumetric flask was added acetonitrile (about 9mL) 
until almost the mark 
 5µL of "Internal standard 2mM in acetonitrile" were added in the 
volumetric flask, shaken thoroughly and made up to the mark with 
acetonitrile 
 Finally, an "Internal standard 1µM in acetonitrile" label was applied 
and an expiry date of 6 months was assigned 
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2.3.4 Stock concentration of 10mM for each chemical to be tested 
  
 In order to have a stock solution of 10mM concentration, a defined 
amount of mg of the desired chemical was weighted and 
transferred in a 5mL volumetric flask 
 About 3mL of acetonitrile were added and checked to ensure that 
all the powder was dissolved. Then maked up to the mark with 
acetonitrile 
 Thoroughly shaken and transferred in a glass tube and labelled as 
“Chemical Name (either Acetaminophen, Diclofenac or Verapamil) 
10mM in acetonitrile” 
 An expiry date of 6 months was assigned 
2.3.5 Working concentration of 2µM for each chemical to be tested  
 
Note: the working concentration was the one to which the cells were 
exposed for the incubation assay to measure in vitro metabolic hepatic 
clearance. 
When the working concentration was added to the cells, the final 
concentration was 1µM. It was also important that the percentage of 
organic solvent was less than 0.1% to avoid potential interference with 
the cells. In this case the percentage of acetonitrile was 0.01% when 
added to the cells. 
 
 Using a calibrated glass syringe, 200µL of a specific chemical stock 
concentration of 10mM were transferred in 1mL volumetric flask, 
and then made up to the mark with "cell medium-acetonitrile 
50:50" solution. 
 After a thorough shaking, the solution was transferred in a glass 
tube and labelled as “Chemical Name (Acetaminophen, Diclofenac 
or Verapamil) 2mM”. An expiry date of 1 day was assigned. 
 Using a calibrated glass syringe, 5µL of "Chemical Name 2mM" 
previously prepared were transferred in 5mL volumetric flask, and 
then made up to the mark with "cell medium for incubation assay" 
solution. 
 Shaken thoroughly, the solution was then transferred in a glass 
tube and labelled as “Chemical Name 2µM in cell medium”. An 
expiry date of 1 day was also assigned. 
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2.3.6 Analytical standards for the calibration curve for the LC-MS 
analysis  
 
From each chemical working concentration at 2µM (Acetaminophen, 
Diclofenac or Verapamil), see section 2.3.5, serial dilutions in 
Williams’ Medium E were made to obtain the following 
concentrations: 1000, 500, 250, 100, 50 and 10 nM. These 
concentrations were prepared in glass vials and then used to build 
the calibration curve. Table 2 shows the procedure used to prepare 
the standards. 
 
 
 
 
2.4 Human in vitro hepatic metabolic clearance method 
 
2.4.1 Study design of the in vitro human hepatic metabolic clearance 
method (or in vitro incubation assay) 
The incubation assay consisted of exposing cryopreserved pooled primary 
human hepatocytes to 1 µM of Acetaminophen, Diclofenac or Verapamil at 
the following time-points: 0, 15, 30, 60, 90 and 120 min.  
At the end of each time point, the incubation reaction is stopped by 
adding a solution of acetonitrile containing a specific Internal Standard 
(either for Acetaminophen, Diclofenac or Verapamil). After centrifugation, 
a certain volume of supernatant is collected, transferred to a glass vial for 
the following chemical analysis by mass spectrometry. 
Table 2 
Concentration 
to be 
prepared 
(nM) 
Volume 
to be 
prepared 
(µL) 
 Volume used of 
more concentrated 
solution 
(µL) 
 Volume of cell 
medium 
added 
(µL) 
1000 1000 
= 
500 (of 2µM) 
+ 
500 
500 1000 500 (of 1000 nM) 500 
250 1000 500 (of 500 nM) 500 
100 1000 100 (of 1000 nM) 900 
50 1000 100 (of 500 nM) 900 
10 1000 100 (of 100 nM) 900 
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The whole incubation assay was done manually by using 96-well clear 
polypropylene plates. 
In one experiment, all the three chemicals can be tested in the same 
plate following the layout described below. Figure 2 shows the schematic 
representation of how the samples are organised in a 96-well plate. 
The plate layout shown in Figure 2 was then used for each of the time-
points (0, 15, 30, 60, 90 and 120 min). In order to check that cell 
viability was not influenced by addition of the chemical, cell count was 
normally measured at the beginning and end of incubation assay (in this 
case 0 and 120 min). For this experiment, cell count was also measured 
at the other time-points (15, 30, 60 and 90 min) in order to monitor the 
number of cells during the whole incubation period. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2 
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2.4.1.1 Prepare equipment for incubation assay 
 
 6 sterile 96-well clear polypropylene plates with lid, round bottom, 
uncoated were taken. For each plate, the lid was labelled writing 
the corresponding incubation time (e.g. 0, 15, 30, 60, 90 or 120 
min) 
 To each plate, 50µL of "Verapamil (or another chemical) working 
concentration of 2µM" (see section 2.3.5) were added to 3 wells, 
as shown in Figure 2. The position of these wells, which were used 
as technical replicates, was marked 
 To each plate, 50µL of "Verapamil (or another chemical) working 
concentration of 2µM" (see section 2.3.5) and then 50µL of cell 
medium (see section 2.3.1) were added to 3 wells, as shown in 
Figure 2. Also in this case, the position of these wells which were 
used as negative controls was marked 
 All 96-well plates were put in the incubator at 37°C and 5% CO2 
for 10-15min prior to cell addition 
 
2.4.1.2 Thawing and reconstitution of cryopreserved human hepatocytes 
 
 The cell medium was pre-warmed (see section 2.3.1) to 37°C for 
about 20-30min 
The following steps have taken about 30 min. 
 
Notes: 
* The thawing procedure is stressful to frozen cells, and working 
quickly ensures that a high proportion of the cells survive the 
procedure. 
* 1 vial contained about 5 million of frozen hepatocytes. Since, for the 
incubation assay, each well contained 50000 cells, plus 3 chemicals 
in triplicate, 6 time points and controls (50000 x 3 chemicals x 3 
replicates x 6 time points = >2700000 cells), 1 vial was enough to 
perform an experiment following the layout shown in Figure 2. 
 48mL of thawing medium (see section 2.2.2) were transferred to a 
sterile 50mL polystyrene tube 
 The thawing medium was prewarmed to 37°C for about 10min 
 After, the vial from the shipping container or cryostorage was 
carefully removed. If the vial has been stored in the liquid phase, 
it is necessary to ensure that liquid nitrogen is removed from the 
vial before warming up and check that the cap is firmly closed. 
 The vial was immersed into a 37°C water bath and gently shaken 
for about 1.5 minutes until the ice was detached from the plastic 
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 The vial was transferred into the laminar flow hood and disinfected 
with an absorbent paper containing isopropanol or ethanol 
 From the vial, all hepatocytes cell suspension were transferred into 
the pre-warmed 50mL polystyrene tube containing 48mL of 
thawing medium 
 From the 50mL polystyrene tube, 1mL of solution was used to 
rinse the vial once to take what remains of cells. Then, transferred 
back into the 50mL polystyrene tube 
 The hepatocytes suspension was reached by gently inverting the 
50mL polystyrene tube 3 times 
 The 50mL polystyrene tube was centrifuged at 50g at room 
temperature during 5 minutes 
 The supernatant was discarded by either pouring in one motion 
(partial pouring and re-inverting the centrifuge tube is 
inadequate), or aspirating using a vacuum pump 
 4mL of pre-warmed cell medium were added to the 50mL 
polystyrene tube. Then, a pipette 100-1000µL was used to pipette 
gently for loosening the pellet 
 The total cell count and the percentage of viable cells were 
determined using the Trypan Blue exclusion method 
 After determination of the cell concentration (expressed as 
cells/mL), a dilution with pre-warmed cell medium was made to 
obtain the desired concentration of cells (for the incubation assay 
50000 cells in 50µL are needed. Therefore the desired final 
concentration is 1 million cells in 1mL of cell medium) 
 
Acceptance criteria to use hepatocytes for incubation assay 
Two conditions must be taken into account when performing the 
incubation assay: 
 A minimum cell viability of 80% after thawing must be obtained. 
 After reconstitution, cell suspensions can be used for up to 4 
hours. 
 
2.4.1.3 Incubation assay 
 
 Firstly, from the incubator, only the 96-well plate labelled on the 
lid as "0min" was removed 
 50µL of viable hepatocytes (1 million cells/mL) were added only to 
the 3 wells used as technical replicates (see section 2.4.1.1) 
 Immediately, from each of the 6 wells of the first column 
containing Verapamil-exposed samples (see Figure 2), 70µL were 
transferred, by using a multichannel pipette, into the 
corresponding new column as shown in Figure 2. Then, 70µL of 
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"stop solution with Verapamil Internal Standard (see section 
2.3.3) were immediately added to each well 
 The previous step was repeated for the remaining two chemicals: 
Diclofenac and Acetaminophen and consequently followed the 
complete procedure as described below 
 The 96-well plate was centrifuged at 1300g for 10min at 4°C. 
Then, from each well 100µL of supernatant were transferred in the 
corresponding previously-labelled glass vials which were stored at 
low temperature (-70°C) until LC-MS analysis 
 From the incubator, all the remaining 96-well plates were removed 
and placed on the heating plate (those labelled on the lid as "15, 
30, 60, 90 and 120 min") 
 In order to start the incubation reaction, 50µL of viable 
hepatocytes (1 million cells/mL) were added, only to the wells 
used as technical replicates (see Figure 2). Furthermore, 50µL of 
viable hepatocytes were added to each plate, into one well which 
was used for cell-count (Figure 2) 
 The 96-well plates were returned to the orbital shaker in the 
incubator at 37°C and the shaker speed was adjusted at 300 rpm 
 At each time-point of 15, 30, 60, 90 and 120 min, the 
corresponding 96-well plate was removed from the incubator. 
 Immediately, from each of the 6 wells of the first column 
containing Verapamil-exposed samples (see Figure 2), 70µL were 
transferred, by using a multichannel pipette, into the 
corresponding new column as shown in Figure 2. Then, 70µL of 
"stop solution with Verapamil Internal Standard (see section 
2.3.3) were immediately added to each well 
 The previous step was repeated for the remaining two chemicals: 
Diclofenac and Acetaminophen 
Note: it was important to record the exact time when the stop solution 
was added to the samples 
 The 96-well plate was centrifuged at 1300g for 10min at 4°C. 
Then, 100µL of supernatant from each well were transferred in the 
corresponding previously-labelled glass vials which were stored at 
low temperature (-70°C) until LC-MS analysis. 
 
2.4.1.4 Preparation of analytical standards 
  
For each chemical, the prepared standards (see section 2.3.6) were 
obtained following the same procedure used for the preparation of the 
samples as described in section 2.4.1.3. 
Briefly, from each standard 70µL were transferred to a new glass vial, 
previously labelled. Then 70µL of "stop solution with corresponding 
Internal Standard (see section 2.3.3)" were added. The glass vials were 
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then centrifuged at 1300g for 10min at 4°C. Then, 100µL of supernatant 
were transferred in a new previously-labelled glass vials which were 
stored at -70°C until LC-MS analysis. 
 
2.4.2 LC-MS/MS analysis 
The mass spectrometer was a Xevo G2-S QTof (Waters) coupled with an 
Acquity Ultra Performance Liquid Chromatography (UPLC) system 
(Waters) and interfaced with an ElectroSpray Ion source (ESI). 
For all 3 chemicals the column used was a 50×2.1mm, Acquity UPLC-BEH 
C18 1.7μm. Mobile phase A was an aqueous solution of 0.1% formic acid 
and as mobile phase B was used 100% acetonitrile containing 0.1% of 
formic acid. 
The chromatographic conditions for Diclofenac and Verapamil were the 
same as shown in Table 3. 
 
Table 3 
Time (min) Flow rate (mL/min) A (%) B (%) 
0 0.4 98 2 
0.5 0.4 98 2 
2.5 0.4 20 80 
2.51 0.4 2 98 
4.5 0.4 2 98 
4.51 0.4 98 2 
6 0.4 98 2 
 
The chromatographic conditions for acetaminophen are shown in Table 4. 
 
Table 4 
Time (min) Flow rate (mL/min) A (%) B (%) 
0 0.4 98 2 
0.4 0.4 98 2 
2.2 0.4 2 98 
3 0.4 2 98 
3.1 0.4 98 2 
4 0.4 98 2 
 
 
For Diclofenac and Verapamil the instrument operated in MS/MS mode in 
which the parent ion was selected in the quadrupole and then 
fragmented. The resulting product ions were monitored for the 
quantitative analysis. For Acetaminophen the instrument operated in MSe 
mode and no specific product ions were selected for the quantitative 
analysis. 
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Table 5 summarises the source parameters optimised for each chemicals. 
 
Table 5 
Instrumental Parameters Settings 
Test Chemical 
Acetaminophen Diclofenac Verapamil 
Polarity ionisation Positive Negative Positive 
Capillary (kV) 1 0.5 0.4 
Cone (V) 40 100 40 
Source Temperature (°C) 120 120 120 
Desolvation Temperature (°C) 350 500 500 
Cone Gas Flow (L/h) 50 50 50 
Desolvation Gas Flow (L/h) 1000 1000 1000 
 
Table 6 summarises the precursor- and product-ion(s) monitored for 
each chemical and used for the quantitative analysis. Diclofenac 
quantification, the precursor/product ion pair m/z 250/214 was used as 
quantifier, while the pair at m/z 455/303 was used for verapamil. 
 
 
Table 6 
 
Chemical Polarity MS mode Precursor ion 
(m/z) 
Product ion 
(m/z) 
Acetaminophen positive MSe 151.06 - 
Acetaminophen-D4 positive MSe 155.08 - 
Diclofenac negative MS/MS 250.01 
178.06 
214.04 
Diclofenac 13C6 negative MS/MS 256.08 220.11 
Verapamil positive MS/MS 455.29 
165.09 
303.20 
Verapamil-D7 positive MS/MS 462.33 310.29 
 
 
2.4.3 Calculation of in vitro intrinsic clearance (CLint) 
 
The calculated concentrations, expressed as nM, have been transformed 
into a natural logarithmic scale (ln). 
Then the elimination rate constant (k) was calculated from the slope of 
ln(Ct/C0) vs t (min), with a 1/y weighting, according to equation 1.  
 
            ln(
𝐶𝑡
𝐶0
) =  −𝑘𝑡               (eq. 1) 
 
Ct = the substrate concentration in the incubation well at time t (min) 
C0 = the substrate concentration in the incubation well at time t= 0 
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k = the elimination rate constant  
 
The intrinsic clearance in vitro (CLint in vitro) was calculated according to 
the following equation:  
                              𝐶𝐿𝑖𝑛𝑡 =  
𝑘𝑉
𝑁
                       μL/ (min*millions of cells)  
 
Where: 
 𝑘 =  
0.639
𝑡1/2
 
 V = incubation volume (100 μL)  
 N = number of cells (x106) in the incubation (50000 cells used in 
this assay)  
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3 Results 
 
3.1 LC-MS analysis 
 
Verapamil and diclofenac were eluted at 2.10 and 2.65 min, respectively 
while the retention time of acetaminophen was eluted at 1.21 min. 
Figure 3 shows the chromatogram for each chemical. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A linear response was observed in the range 10–1000 nM in cell medium 
for all 3 chemicals. For all chemicals, the limit of quantification (LOQ) is 
10 nM while the limited of detection (LOD) is 1 nM. 
Between- and within-day precision and accuracy were always below 20% 
for both the analytes and no carry-over was observed (data not shown). 
 
 
 
Acetaminophen std 125 nM 
in cell medium 
Verapamil std 10 nM in cell 
medium 
Diclofenac std 10 nM in cell 
medium 
Figure 3 
 21 
 
3.2 In vitro hepatic metabolic clearance 
 
Following the experimental protocol described in section 2.4.1, three 
experiments were performed by exposing cells to Diclofencac or 
Verapamil and two experiments by adding Acetaminophen to the cells. 
In each experiment, samples were run in triplicate (as shown in Figure 
2). 
The reproducibility between experiments was good as shown in Figure 4, 
5 and 6 and Table 7.  
The concentration of Diclofenac and Verapamil decreased over time 
indicating that these two chemicals were bio-transformed. 
Regarding acetaminophen, no significant difference in concentration over 
time was observed within the 2 h exposure. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4 
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Figure 5 
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Figure 6 
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The values of intrinsic clearance (calculated following equations in section 
2.4.3) for diclofenac and verapamil are shown in Table 7. 
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4 Conclusion 
 
Knowledge of in vitro human hepatic metabolic clearance can improve the 
prediction of chemical's toxicity by using alternatives to animal testing 
methods and therefore better support chemical risk assessment. 
This report describes the preliminary work done at the EURL ECVAM 
laboratory facility to describe an experimental procedure towards a 
representative in vitro human hepatic metabolic clearance method that 
can be ultimately used in future defined approaches for toxicological risk 
assessment. 
The method implemented was based on a collective knowledge-gathering 
exercise in which existing available in vitro human hepatic metabolic 
clearance methods were mapped and compared. The method 
implemented, represented the most common experimental features used 
by the existing methods gathered while doing the mapping exercise. 
As preliminary work, three chemicals with known in vivo human hepatic 
metabolic clearance data were used to challenge the in vitro method 
implemented in the EURL ECVAM laboratory. 
The scope of the project was to evaluate the reproducibility of the data 
(concentration-time curves and calculated in vitro intrinsic clearance) 
between the different experimental runs performed. 
The data obtained clearly show good reproducibility. 
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